Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Double Blind Comparative Clinical Study Evaluating Pharmacokinetics and Safety in Single Intravenous Use of Pertuzumab (Manufactured by Mabscale, LLC) Compared to Perjeta® in Healthy Men

NCT05825781 is registered in ClinicalTrials.gov with Mabscale, LLC as lead sponsor.

NCT NCT05825781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05825781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Double Blind Comparative Clinical Study Evaluating Pharmacokinetics and Safety in Single Intravenous Use of Pertuzumab (Manufactured by Mabscale, LLC) Compared to Perjeta® in Healthy Men
Lead sponsor
Mabscale, LLC
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 20, 2023
Completion date
September 30, 2024
Enrollment
114 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy men